MarketCapExport financials
Quest Diagnostics Incorporated (DGX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Quest Diagnostics Incorporated Balance Sheet 2025-2006 | DGX
Brief overview of Quest Diagnostics Incorporated's balance sheet strength
The comparison uses five available annual reports from the 2015–2019 interval.
The balance sheet expanded from $10 billion to $12.8 billion. Growth of +28.9% and CAGR of 6.6% look measured and sustainable.
Assets and liabilities changed at similar rates, +28.9% and +36.3%. The funding mix did not shift sharply.
Equity finances 43.9% of the balance sheet, compared with 47% at the start. The cushion remains adequate.
Net debt to equity stands at 0.63x; debt servicing is an important part of overall resilience.
Cash accounts for 9.3% of assets versus 1.3% initially. The change indicates the degree of financial flexibility.
By the end of the period, accumulated earnings were $8.2 billion; the change from the start was +31.9%.
What the balance sheet shows
Quest Diagnostics Incorporated's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Quest Diagnostics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
4.92 B | 5.24 B | 3.88 B | 3.82 B | 3.29 B | 3 B | 3.58 B | 3.76 B | 3.65 B | 3.38 B | 3.52 B | 3.57 B | 3.14 B | 3.07 B | 3.86 B | 2.54 B | 2.57 B | 2.83 B | - | - |
Long Term Debt |
5.17 B | 5.62 B | 4.41 B | 3.98 B | 4.01 B | 4.01 B | 3.97 B | 3.43 B | 3.75 B | 3.73 B | 3.49 B | 3.24 B | 3.12 B | 3.35 B | 3.37 B | 2.64 B | 2.94 B | 3.08 B | - | - |
Long Term Debt Current |
174 M | 173 M | 153 M | 153 M | 151 M | 141 M | 145 M | 464 M | 36 M | 6 M | 159 M | 518 M | 212 M | 9.4 M | 569 M | 349 M | 171 M | 5.14 M | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 5.17 B | 4.25 B | 4.49 B | 4.46 B | 4.08 B | 3.84 B | 3.84 B | 4.05 B | 4.04 B | - | - | - | - | - |
Total Current Liabilities |
2.28 B | 2.17 B | 1.82 B | 1.55 B | 1.75 B | 1.78 B | 1.99 B | 1.48 B | 1.06 B | 981 M | 1.17 B | 1.71 B | 1.13 B | 1.05 B | 1.56 B | 1.21 B | 1.06 B | 1.22 B | - | - |
Total Liabilities |
- | - | - | - | - | - | 7.16 B | 5.74 B | 5.55 B | 5.44 B | 5.25 B | 5.55 B | 4.98 B | 5.1 B | 5.6 B | - | - | - | - | - |
Retained Earnings |
9.99 B | 9.36 B | 8.82 B | 8.29 B | 7.65 B | 9.3 B | 8.17 B | 7.6 B | 7.14 B | 6.61 B | 6.2 B | 5.72 B | 5.36 B | 4.69 B | 4.26 B | 3.87 B | 3.22 B | 2.56 B | - | - |
Total Assets |
16.2 B | 16.2 B | 14 B | 12.8 B | 13.6 B | 14 B | 12.8 B | 11 B | 10.5 B | 10.1 B | 9.96 B | 9.88 B | 8.95 B | 9.28 B | 9.31 B | 8.53 B | 8.56 B | 8.4 B | - | - |
Cash and Cash Equivalents |
420 M | 549 M | 686 M | 315 M | 872 M | 1.16 B | 1.19 B | 135 M | 137 M | 359 M | 133 M | 192 M | 187 M | 296 M | 165 M | 449 M | 534 M | 254 M | 168 M | 150 M |
Book Value |
16.2 B | 16.2 B | 14 B | 12.8 B | 13.6 B | 14 B | 5.69 B | 5.27 B | 4.96 B | 4.66 B | 4.71 B | 4.33 B | 3.97 B | 4.19 B | 3.71 B | 8.53 B | 8.56 B | 8.4 B | - | - |
Total Shareholders Equity |
7.17 B | 6.78 B | 6.31 B | 5.89 B | 6.48 B | 6.81 B | 5.64 B | 5.22 B | 4.92 B | 4.63 B | 4.68 B | 4.3 B | 3.95 B | 4.16 B | 3.69 B | 4.03 B | 3.99 B | 3.6 B | 3.35 B | 3.04 B |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Quest Diagnostics Incorporated
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
5.63 B | 5.16 B | 5.17 B | 5.17 B | 5.86 B | 5.65 B | 3.82 B | 3.8 B | 3.95 B | 3.78 B | 3.98 B | 3.98 B | 3.98 B | - | 3.98 B | 4.01 B | 4.01 B | 4.01 B | 4.01 B | 4.01 B | 4.02 B | 4.02 B | 4.03 B | 3.97 B | 3.97 B | 3.97 B | 3.97 B | 3.43 B | 3.43 B | 3.43 B | 3.43 B | 3.75 B | 3.75 B | 3.75 B | 3.75 B | 3.73 B | 3.82 B | 3.84 B | 3.74 B | 3.49 B | 3.49 B | 3.49 B | 3.49 B | 3.22 B | 3.22 B | 3.22 B | 3.24 B | 3.12 B | 3.33 B | 3.33 B | 3.33 B | 3.36 B | 3.35 B | 3.35 B | 3.35 B | 3.94 B | 3.37 B | 3.37 B | 3.37 B | 2.84 B | 2.97 B | 2.94 B | 2.88 B | 2.88 B |
Retained Earnings |
10.4 B | 10.2 B | 9.84 B | 9.68 B | 9.49 B | 9.22 B | 9.08 B | 8.94 B | 8.71 B | 8.57 B | 8.41 B | 8.29 B | 8.26 B | - | 7.93 B | 7.65 B | 7.33 B | 10.2 B | 9.69 B | 9.3 B | 9.3 B | 9.3 B | 9.3 B | 8.17 B | 8.17 B | 8.17 B | 8.17 B | 7.6 B | 7.6 B | 7.6 B | 7.6 B | 7.14 B | 7.14 B | 7.14 B | 7.14 B | 6.61 B | 6.61 B | 6.61 B | 6.61 B | 6.2 B | 6.2 B | 6.2 B | 6.2 B | 5.72 B | 5.72 B | 5.72 B | 5.72 B | 5.36 B | 5.36 B | 5.36 B | 5.36 B | 4.69 B | 4.69 B | 4.69 B | 4.69 B | 4.26 B | 4.26 B | 4.26 B | 4.26 B | 3.72 B | 3.54 B | 3.36 B | 3.05 B | 2.88 B |
Total Assets |
16.9 B | 16.7 B | 16.2 B | 16 B | 15.8 B | 16.1 B | 13.9 B | 14 B | 13.5 B | 13.4 B | 12.8 B | 12.8 B | 13.2 B | - | 13.4 B | 13.6 B | 13.6 B | 12.9 B | 13.9 B | 14 B | 14 B | 14 B | 14 B | 12.8 B | 12.8 B | 12.8 B | 12.8 B | 11 B | 11 B | 11 B | 11 B | 10.5 B | 10.5 B | 10.5 B | 10.5 B | 10.1 B | 10.1 B | 10.1 B | 10.1 B | 9.96 B | 9.96 B | 9.96 B | 9.96 B | 9.86 B | 9.86 B | 9.86 B | 9.88 B | 8.95 B | 8.95 B | 8.95 B | 8.95 B | 9.28 B | 9.28 B | 9.28 B | 9.28 B | 9.31 B | 9.31 B | 9.31 B | 9.31 B | 8.46 B | 8.48 B | 8.52 B | 8.37 B | 8.21 B |
Cash and Cash Equivalents |
626 M | 393 M | 432 M | 319 M | 188 M | 764 M | 271 M | 474 M | 143 M | 126 M | 175 M | 315 M | 700 M | 790 M | 712 M | 872 M | 987 M | 560 M | 1.23 B | 1.16 B | 1.16 B | 1.16 B | 1.16 B | 1.19 B | 1.19 B | 1.19 B | 1.19 B | 135 M | 135 M | 135 M | 135 M | 137 M | 137 M | 137 M | 137 M | 359 M | 359 M | 359 M | 359 M | 133 M | 133 M | 133 M | 133 M | 192 M | 192 M | 192 M | 192 M | 187 M | 187 M | 187 M | 187 M | 296 M | 296 M | 296 M | 296 M | 165 M | 165 M | 165 M | 165 M | 369 M | 448 M | 463 M | 247 M | 119 M |
Book Value |
16.9 B | 16.7 B | 16.2 B | 16 B | 15.8 B | 16.1 B | 13.9 B | 14 B | 13.5 B | 13.4 B | 12.8 B | 12.8 B | 13.2 B | - | 13.4 B | 13.6 B | 13.6 B | 12.9 B | 13.9 B | 14 B | 14 B | 14 B | 14 B | 12.8 B | 12.8 B | 12.8 B | 12.8 B | 11 B | 11 B | 11 B | 11 B | 10.5 B | 10.5 B | 10.5 B | 10.5 B | 10.1 B | 10.1 B | 10.1 B | 10.1 B | 9.96 B | 9.96 B | 9.96 B | 9.96 B | 9.86 B | 9.86 B | 9.86 B | 9.88 B | 8.95 B | 8.95 B | 8.95 B | 8.95 B | 9.28 B | 9.28 B | 9.28 B | 9.28 B | 9.31 B | 9.31 B | 9.31 B | 9.31 B | 8.46 B | 8.48 B | 8.52 B | 8.37 B | 8.21 B |
Total Shareholders Equity |
7.52 B | 7.37 B | 7.26 B | 7.23 B | 6.96 B | 6.84 B | 6.66 B | 6.47 B | 6.46 B | 6.29 B | 6.09 B | 5.89 B | 6.27 B | 6.45 B | 6.42 B | 6.44 B | 6.43 B | 5.9 B | 6.74 B | 6.76 B | 6.76 B | 6.76 B | 6.76 B | 5.64 B | 5.64 B | 5.64 B | 5.64 B | 5.22 B | 5.22 B | 5.22 B | 5.22 B | 4.92 B | 4.92 B | 4.92 B | 4.92 B | 4.63 B | 4.63 B | 4.63 B | 4.63 B | 4.68 B | 4.68 B | 4.68 B | 4.68 B | 4.3 B | 4.3 B | 4.3 B | 4.3 B | 3.95 B | 3.95 B | 3.95 B | 3.95 B | 4.16 B | 4.16 B | 4.16 B | 4.16 B | 3.69 B | 3.69 B | 3.69 B | 3.69 B | 3.86 B | 3.92 B | 3.9 B | 3.91 B | 3.74 B |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Quest Diagnostics Incorporated, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Fulgent Genetics
FLGT
|
$ 19.81 | 1.57 % | $ 610 M |  USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Illumina
ILMN
|
$ 262.54 | 0.3 % | $ 40.7 B | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Laboratory Corporation of America Holdings
LH
|
$ 317.95 | 0.09 % | $ 26.5 B | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Lantheus Holdings
LNTH
|
$ 99.7 | 0.03 % | $ 6.73 B | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.67 | 4.71 % | $ 86.7 K | USA |
 |
Medpace Holdings
MEDP
|
$ 618.47 | 1.94 % | $ 17.8 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
$ 56.58 | 0.67 % | $ 2.65 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 622.29 | 0.12 % | $ 33.4 B |  Schweiz |
 |
NeoGenomics
NEO
|
$ 16.65 | 2.19 % | $ 2.13 B | USA |
 |
Neogen Corporation
NEOG
|
$ 11.81 | 0.73 % | $ 2.57 B | USA |
 |
CareDx, Inc
CDNA
|
$ 64.0 | 3.07 % | $ 3.41 B | USA |
 |
National Research Corporation
NRC
|
$ 20.15 | 3.33 % | $ 451 M | USA |
 |
Danaher Corporation
DHR
|
$ 229.04 | 3.04 % | $ 163 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 25.74 | 0.98 % | $ 24.4 B |  Niderland |
 |
Brainsway Ltd.
BWAY
|
$ 11.44 | 2.69 % | $ 389 M | Israel |
 |
Precipio
PRPO
|
$ 21.38 | 1.3 % | $ 34.3 M | USA |
 |
RadNet
RDNT
|
$ 68.8 | 1.81 % | $ 5.17 B | USA |
 |
Castle Biosciences
CSTL
|
$ 31.96 | 2.08 % | $ 926 M | USA |
 |
Guardant Health
GH
|
$ 158.6 | 1.77 % | $ 19.9 B | USA |
 |
Senseonics Holdings
SENS
|
$ 7.77 | 1.6 % | $ 324 M | USA |
 |
DarioHealth Corp.
DRIO
|
$ 4.82 | 0.97 % | $ 19.2 M | Israel |
 |
DexCom
DXCM
|
$ 86.04 | 0.07 % | $ 33.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 266.9 | 0.11 % | $ 45.9 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
VolitionRx Limited
VNRX
|
$ 0.18 | 5.31 % | $ 22.6 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 436.95 | 0.65 % | $ 26 B | USA |
 |
Exagen
XGN
|
$ 7.72 | 1.66 % | $ 166 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.25 | 0.36 % | $ 6.81 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 170.18 | 3.65 % | $ 13.3 B |  Irlanda |
 |
ENDRA Life Sciences
NDRA
|
$ 4.85 | 6.81 % | $ 3.82 M | USA |
 |
OPKO Health
OPK
|
$ 1.53 | 0.62 % | $ 1.15 B | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 690.0 | 3.46 % | $ 260 B | USA |
 |
Twist Bioscience Corporation
TWST
|
$ 132.75 | 0.45 % | $ 7.94 B | USA |
 |
Sotera Health Company
SHC
|
$ 17.89 | 0.03 % | $ 5.08 B | USA |
 |
Natera
NTRA
|
$ 393.44 | 2.54 % | $ 53.8 B | USA |
 |
QIAGEN N.V.
QGEN
|
$ 46.13 | 0.15 % | $ 10 B | Niderland |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |